ALLO
Allogene Therapeutics Inc
1.50$
+4.3%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Allogene Therapeutics Inc (ALLO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -32 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 0.0 | -6.0 | -17 | -21 | -30 | -25 | -32 | -50 | -41 | -27 | -38 | -10.0 | -49 | -41 | -49 | -45 | -68 | -43 | -48 | -62 | -67 | -62 | -56 | -54 | -56 | -64 | -44 | -37 | -53 | -39 | -30 | -28 | -13 | -32 | -102 | |
| – | 0.4 | 0.5 | 0.5 | 0.5 | 0.7 | 1.1 | 1.3 | 1.9 | 2.0 | 1.9 | 1.8 | 1.8 | 1.9 | 2.0 | 2.3 | 4.2 | 3.7 | 3.7 | 3.9 | 3.1 | 3.5 | 3.6 | 3.6 | 3.5 | 3.6 | 3.6 | 3.2 | 3.2 | 3.1 | 3.1 | 3.1 | 3.1 | 2.9 | 2.6 | 12 | |
| – | – | 8.1 | 4.6 | 5.9 | 7.9 | 11 | 13 | 14 | 14 | 17 | 18 | 16 | 17 | 21 | 21 | 22 | 22 | 23 | 21 | 17 | 19 | 17 | 15 | 15 | 12 | 14 | 13 | 13 | 12 | 8.7 | 8.7 | 8.1 | 8.3 | 12 | 37 | |
| – | 25 | 59 | 25 | 7.3 | 9.1 | 12 | 16 | 16 | 15 | 17 | 17 | 20 | 17 | 24 | 21 | 22 | 22 | 23 | 21 | 19 | 19 | 17 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 2.6 | 11 | -2.3 | 0.9 | -7.2 | 4.7 | 2.2 | -6.5 | -3.2 | 15 | 7.2 | 35 | -39 | 3.9 | 3.4 | -0.1 | -20 | 5.1 | 7.8 | 11 | 7.4 | -4.4 | -15 | -3.4 | -4.4 | -17 | 21 | 5.3 | -8.3 | -2.2 | -0.1 | -0.2 | 18 | -0.6 | 17 | |
| 0.0 | 1.4 | 0.5 | 1.4 | 1.3 | 10 | 7.9 | 18 | 14 | 12 | 16 | 20 | 17 | 6.5 | 11 | 3.3 | 0.7 | 1.9 | 1.4 | 0.2 | 1.7 | 1.0 | 0.3 | 0.0 | 0.2 | 0.0 | 0.0 | 0.4 | 0.3 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.2 | 0.4 | |
| – | -317 | -2.6 | -317 | -313 | 33 | 44 | 79 | 7.9 | -15 | -429 | -83 | 22 | 97 | 25 | 13 | 29 | -22 | 54 | 25 | 50 | 113 | 17 | -34 | 67 | 22 | 75 | -76 | 55 | 6.2 | 44 | 12 | 34 | -30 | -148 | -132 | |
| – | – | – | 6,076 | 654 | 0.7 | 0.2 | 1.6 | 1.8 | 1.4 | 600 | 3.9 | 2.8 | 2.0 | 3.2 | 2.4 | 3.6 | 1.5 | 0.0 | 1.1 | 2.5 | 1.7 | 90 | – | 2.5 | 0.9 | – | 0.7 | – | 0.6 | – | 0.3 | – | 0.5 | 0.5 | – | |
| – | 117 | 117 | 117 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 274 | 153 | 274 | 345 | 0.7 | 0.2 | 1.6 | 56 | 17 | 600 | 3.9 | 13 | 6.0 | 3.2 | 2.4 | 0.3 | 1.8 | 0.0 | 1.1 | 0.0 | 1.7 | 90 | 4.3 | 0.2 | 1.7 | 109 | 0.7 | 5.7 | 14 | 5.1 | 3.2 | 7.9 | 21 | 188 | 220 | |
| – | 0.0 | 144 | -60 | 9.7 | 3.3 | 20 | 48 | 14 | -39 | 144 | -117 | 25 | 54 | -13 | -33 | -16 | -89 | 12 | -22 | -12 | 48 | 45 | -86 | 14 | -32 | 120 | -119 | 24 | -33 | 9.9 | -15 | 14 | -21 | 8.3 | -14 | |
| – | 0.0 | -6.6 | -19 | -23 | -41 | -33 | -50 | -64 | -53 | -43 | -58 | -27 | -56 | -52 | -52 | -46 | -70 | -44 | -48 | -64 | -68 | -62 | -56 | -54 | -56 | -64 | -45 | -37 | -53 | -39 | -30 | -28 | -13 | -32 | -103 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.